Routine versus selective protamine administration after transcatheter aortic valve implantation
Routine versus selective protamine administration after transcatheter aortic valve implantation
Key result
Routine versus selective protamine administration after transcatheter aortic valve implantation has pending results from a late-breaking trial at the ESC Congress 2026.
Expert reaction lands here the moment POPular ACE TAVI reports.
POPular ACE TAVI is a 1,000-patient, multicenter, randomized, double-blind, placebo-controlled trial comparing routine versus selective protamine administration after transfemoral TAVI, with a primary endpoint of 30-day all-cause death or clinically relevant bleeding. Results will be presented at ESC 2026 Hot Line 7 by Christiaan Overduin. The trial builds on the earlier ACE-PROTAVI study, which showed routine protamine improved hemostasis and reduced minor vascular complications, and expert commentary suggests positive results could definitively establish protamine use as standard practice post-TAVI.
Tasa de eventos absoluta: 0% vs 0%
Christiaan Overduin (Thu,) reported a other. Routine versus selective protamine administration after transcatheter aortic valve implantation has pending results from a late-breaking trial at the ESC Congress 2026.